Oncternal Therapeutics

$6.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (+5.71%) Today
+$0.04 (+0.62%) As of 8:48 PM UTC after-hours

Why Robinhood?

You can buy or sell ONCT and other stocks, options, and ETFs commission-free!

About ONCT

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T.

CEO
James B. Breitmeyer
Employees
14
Headquarters
San Diego, California
Founded
1997
Market Cap
335.53M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.84M
High Today
$6.55
Low Today
$6.15
Open Price
$6.20
Volume
1.14M
52 Week High
$10.56
52 Week Low
$1.49

ONCT Earnings

-$0.34
-$0.23
-$0.11
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, After Hours

You May Also Like

HYGH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure